This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Duncan, J. R. Articles by Anderson, C. J. Search for Related Content PubMed Articles by Duncan, J. R. Articles by Anderson, C. J.

Indium-111-Diethylenetriaminepentaacetic Acid-Octreotide Is Delivered in Vivo to Pancreatic, Tumor Cell, Renal, and Hepatocyte Lysosomes¹

The Mallinckrodt Institute of Radiology and Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, Missouri 63110

To better understand the factors that govern the target-to-background ratios of ¹¹¹In-diethylenetriaminepentaacetic acid (DTPA) polypeptides, we studied ¹¹¹In-DTPA-octreotide and a model nontargeted compound, ¹¹¹In-DTPA-poly(D)lysine-biotin. We evaluated the fate of ¹¹¹-DTPA-octreotide after it localizes in somatostatin receptor-positive tissues and sought to determine why such a large fraction of these and other ¹¹¹In-DTPA-polypeptides accumulate in the liver and kidneys.

Biodistribution studies in rats with an implanted pancreatic adenocarcinoma demonstrated rapid accumulation of ¹¹¹In-DTPA-octreotide in the pancreas and tumor. Indium-111 also accumulated in the liver and kidneys. Subcellular fractionation of the liver, kidneys, tumor, and pancreas showed that the majority of the radioactivity copurified with lysosomal enzymes. Even at 1 h, little radioactivity was found in the fractions containing a cell surface enzyme. This suggests that in each tissue, the ¹¹¹In-DTPA-octreotide was rapidly shuttled from the cell surface to lysosomes. In the liver, hepatocyte lysosomes were separated from sinusoidal and Kupffer cell lysosomes by administering chloroquine prior to sacrifice. This density shift experiment indicated that ¹¹¹In-DTPA-octreotide accumulated predominantly in hepatocyte lysosomes.

A low molecular weight ¹¹¹In-DTPA-poly(D)lysine-biotin compound was synthesized, and biodistribution studies showed substantial renal accumulation. The poly(D)lysine backbone conferred resistance to degradation, and this fact allowed determination of the distribution of this compound at the cellular level using an antibiotin antibody and immuno-histochemical techniques. These experiments, as well as subcellular fractionation studies, demonstrated that the ¹¹¹In-DTPA-poly(D)lysine-biotin compound accumulated in the lysosomes of proximal renal tubular cells.

These results indicate that lysosomes play a critical role in the cellular physiology of radiolabeled polypeptides. Using these data, we propose a comprehensive model that summarizes the factors that govern the target to background ratios of radiolabeled polypeptides.

¹ This work was funded by NIH Grant R29CA64475 and by grants from Mallinckrodt Medical Inc.

² To whom requests for reprints should be addressed, at Mallinckrodt Institute of Radiology, 510 South Kingshighway Boulevard, St. Louis, MO 63110.

Received 6/21/96. Accepted 12/19/96.

This article has been cited by other articles:

				A. Capello, E. P. Krenning, B. F. Bernard, W. A.P. Breeman, J. L. Erion, and M. de Jong Anticancer Activity of Targeted Proapoptotic Peptides J. Nucl. Med., January 1, 2006; 47(1): 122 - 129. [Abstract] [Full Text] [PDF]

				M. Ginj, K. Hinni, S. Tschumi, S. Schulz, and H. R. Maecke Trifunctional Somatostatin-Based Derivatives Designed for Targeted Radiotherapy Using Auger Electron Emitters J. Nucl. Med., December 1, 2005; 46(12): 2097 - 2103. [Abstract] [Full Text] [PDF]

				F. G. van Schaijk, M. Broekema, E. Oosterwijk, J. E.M. van Eerd, B. J. McBride, D. M. Goldenberg, F. H.M. Corstens, and O. C. Boerman Residualizing Iodine Markedly Improved Tumor Targeting Using Bispecific Antibody-Based Pretargeting J. Nucl. Med., June 1, 2005; 46(6): 1016 - 1022. [Abstract] [Full Text] [PDF]

				S. Froidevaux, M. Calame-Christe, H. Tanner, and A. N. Eberle Melanoma Targeting with DOTA-{alpha}-Melanocyte-Stimulating Hormone Analogs: Structural Parameters Affecting Tumor Uptake and Kidney Uptake J. Nucl. Med., May 1, 2005; 46(5): 887 - 895. [Abstract] [Full Text] [PDF]

				B. Van Den Bossche and C. Van de Wiele Receptor Imaging in Oncology by Means of Nuclear Medicine: Current Status J. Clin. Oncol., September 1, 2004; 22(17): 3593 - 3607. [Abstract] [Full Text] [PDF]

				M. J. Koppe, R. P. Bleichrodt, A. C. Soede, A. A. Verhofstad, D. M. Goldenberg, W. J.G. Oyen, and O. C. Boerman Biodistribution and Therapeutic Efficacy of 125/131I-, 186Re-, 88/90Y-, or 177Lu-Labeled Monoclonal Antibody MN-14 to Carcinoembryonic Antigen in Mice with Small Peritoneal Metastases of Colorectal Origin J. Nucl. Med., July 1, 2004; 45(7): 1224 - 1232. [Abstract] [Full Text] [PDF]

				M. Schottelius, T. Poethko, M. Herz, J.-C. Reubi, H. Kessler, M. Schwaiger, and H.-J. Wester First 18F-Labeled Tracer Suitable for Routine Clinical Imaging of sst Receptor-Expressing Tumors Using Positron Emission Tomography Clin. Cancer Res., June 1, 2004; 10(11): 3593 - 3606. [Abstract] [Full Text] [PDF]

				M. Wang, A. L. Caruano, M. R. Lewis, L. A. Meyer, R. P. VanderWaal, and C. J. Anderson Subcellular Localization of Radiolabeled Somatostatin Analogues: Implications for Targeted Radiotherapy of Cancer Cancer Res., October 15, 2003; 63(20): 6864 - 6869. [Abstract] [Full Text] [PDF]

				L. J. Hofland and S. W. J. Lamberts The Pathophysiological Consequences of Somatostatin Receptor Internalization and Resistance Endocr. Rev., February 1, 2003; 24(1): 28 - 47. [Abstract] [Full Text] [PDF]

				A. Capello, E. P. Krenning, W. A.P. Breeman, B. F. Bernard, and M. de Jong Peptide Receptor Radionuclide Therapy In Vitro Using [111In-DTPA0]Octreotide J. Nucl. Med., January 1, 2003; 44(1): 98 - 104. [Abstract] [Full Text] [PDF]

				W. A.P. Breeman, M. de Jong, J. L. Erion, J. E. Bugaj, A. Srinivasan, B. F. Bernard, D. J. Kwekkeboom, T. J. Visser, and E. P. Krenning Preclinical Comparison of 111In-Labeled DTPA- or DOTA-Bombesin Analogs for Receptor-Targeted Scintigraphy and Radionuclide Therapy J. Nucl. Med., December 1, 2002; 43(12): 1650 - 1656. [Abstract] [Full Text] [PDF]

				S. Froidevaux, M. Calame-Christe, H. Tanner, L. Sumanovski, and A. N. Eberle A Novel DOTA-{alpha}-Melanocyte-Stimulating Hormone Analog for Metastatic Melanoma Diagnosis J. Nucl. Med., December 1, 2002; 43(12): 1699 - 1706. [Abstract] [Full Text] [PDF]

				J. R. Duncan, C. J. Anderson, Y. Arano, C. Hornick, and E. A. Woltering Nuclear Translocation of Somatostatin Analogs J. Nucl. Med., March 1, 2001; 42(3): 529 - 531. [Full Text]

				K. Clarke, F.-T. Lee, M. W. Brechbiel, F. E. Smyth, L. J. Old, and A. M. Scott In Vivo Biodistribution of a Humanized Anti-Lewis Y Monoclonal Antibody (hu3S193) in MCF-7 Xenografted BALB/c Nude Mice Cancer Res., September 1, 2000; 60(17): 4804 - 4811. [Abstract] [Full Text]

				P. M. Smith-Jones, C. Bischof, M. Leimer, D. Gludovacz, P. Angelberger, T. Pangerl, M. Peck-Radosavljevic, G. Hamilton, K. Kaserer, A. Kofler, et al. DOTA-Lanreotide: A Novel Somatostatin Analog for Tumor Diagnosis and Therapy Endocrinology, November 1, 1999; 140(11): 5136 - 5148. [Abstract] [Full Text]

				B. E. Rogers, S. F. McLean, R. L. Kirkman, D. Della Manna, S. J. Bright, C. C. Olsen, A. D. Myracle, M. S. Mayo, D. T. Curiel, and D. J. Buchsbaum In Vivo Localization of [111In]-DTPA-D-Phe -Octreotide to Human Ovarian Tumor Xenografts Induced to Express the Somatostatin Receptor Subtype 2 Using an Adenoviral Vector Clin. Cancer Res., February 1, 1999; 5(2): 383 - 393. [Abstract] [Full Text] [PDF]